Want to see HK:3737 full AI Analyst Report?
Zhongzhi Pharmaceutical Holdings Limited (3737) AI Stock Analysis
Zhongzhi Pharmaceutical Holdings Limited
(HKEX:3737)
The overall score reflects solid balance-sheet strength and low leverage as the key support, offset by weakening margins and volatile cash flows, while a constructive but stretched technical setup and a high-yield yet demanding valuation keep the stock in a cautiously neutral zone.
Zhongzhi Pharmaceutical Holdings Limited (3737) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 527.34M
- Dividend Yield
- 8.00%
- Average Volume (3M)
- 391.58K
- Price to Earnings (P/E)
- 24.9
- Beta (1Y)
- 0.01
- Revenue Growth
- -15.17%
- EPS Growth
- -11.41%
- Country
- Hong Kong
- Employees
- 2,168
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Zhongzhi Pharmaceutical Holdings Limited Business Overview & Revenue Model
Company Description
Zhongzhi Pharmaceutical Holdings Limited, an investment holding firm based in the People's Republic of China, focuses on the entire lifecycle of pharmaceutical products, from research and development to manufacturing and distribution. Its operations...
Zhongzhi Pharmaceutical Holdings Limited Financial Statement Overview
Summary
Financials show a strong, low-leverage balance sheet but weakening profitability and inconsistent cash generation, with 2025 revenue contraction and margin compression driving a below-average overall profile.
Income Statement
45NeutralBalance Sheet
75PositiveCash Flow
55Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.65B | 1.74B | 2.21B | 2.05B | 1.83B | 1.75B |
| Gross Profit | 875.92M | 940.25M | 1.29B | 1.22B | 1.07B | 1.06B |
| EBITDA | 112.49M | 99.81M | 230.91M | 317.53M | 199.89M | 164.63M |
| Net Income | 17.62M | 17.29M | 95.21M | 162.78M | 106.39M | 52.13M |
Balance Sheet | ||||||
| Total Assets | 1.76B | 1.83B | 1.99B | 1.79B | 1.88B | 1.52B |
| Cash, Cash Equivalents and Short-Term Investments | 185.38M | 200.89M | 167.10M | 166.65M | 419.36M | 242.18M |
| Total Debt | 87.63M | 227.02M | 188.60M | 225.06M | 170.86M | 175.74M |
| Total Liabilities | 655.45M | 732.02M | 865.58M | 739.30M | 869.31M | 622.94M |
| Stockholders Equity | 1.10B | 1.10B | 1.12B | 1.05B | 1.00B | 898.74M |
Cash Flow | ||||||
| Free Cash Flow | 63.77M | 69.88M | 39.62M | -69.93M | 196.17M | -7.47M |
| Operating Cash Flow | 94.71M | 104.19M | 181.48M | 101.50M | 284.57M | 178.38M |
| Investing Cash Flow | -32.92M | -52.73M | -120.06M | -202.76M | 13.38M | -135.98M |
| Financing Cash Flow | -82.78M | -117.07M | -58.73M | -154.62M | -68.14M | -40.83M |
Zhongzhi Pharmaceutical Holdings Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3737, the sentiment is Negative. The current price of 0.63 is below the 20-day moving average (MA) of 0.68, below the 50-day MA of 0.70, and below the 200-day MA of 0.74, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 33.21 is Neutral, neither overbought nor oversold. The STOCH value of 69.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:3737.
Zhongzhi Pharmaceutical Holdings Limited Peers Comparison
Overall Rating
HK:023977Outperform
HK:095068Neutral- HK:373759Neutral
HK:089758.6Neutral
HK:085854Neutral
HK:101142Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:0239 | 77Outperform | HKD 774.43M | 7.76 | 13.59% | 7.44% | 10.63% | 39.44% |
| HK:0950 | 68Neutral | HKD 606.50M | 3.64 | 8.02% | 5.61% | 7.05% | 22.46% |
| HK:3737 | 59Neutral | HKD 529.37M | 24.90 | 1.60% | 8.00% | -15.17% | -11.41% |
| HK:0897 | 59Neutral | HKD 401.18M | 100.00 | 0.34% | ― | -8.30% | -44.44% |
| HK:0858 | 54Neutral | HKD 147.90M | -0.13 | -154.56% | ― | -7.12% | -523.61% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:1011 | 42Neutral | HKD 440.16M | -5.84 | 14.19% | ― | 100.34% | 83.97% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:3737 | Zhongzhi Pharmaceutical Holdings Limited | 0.63 | 0.01 | 0.81% | |
| HK:0858 | Extrawell Pharmaceutical Holdings Limited | 0.05 | -0.04 | -44.57% | |
| HK:0897 | Wai Yuen Tong Medicine Holdings Limited | 0.36 | -0.10 | -21.74% | |
| HK:0950 | Lee's Pharmaceutical Holdings Limited | 1.03 | -0.77 | -42.94% | |
| HK:1011 | China NT Pharma Group Co., Ltd. | 0.24 | -0.54 | -68.59% | |
| HK:0239 | Pak Fah Yeow International Limited | 2.48 | 0.25 | 11.09% |
Zhongzhi Pharmaceutical Holdings Limited Corporate Events
Zhongzhi Pharmaceutical Posts Lower Revenue but Slight Profit Gain in First Half 2026
Zhongzhi Pharmaceutical Holdings Limited, a Hong Kong-listed pharmaceutical group incorporated in the Cayman Islands, focuses on manufacturing and selling pharmaceutical products in the Chinese market. The company derives its revenue primarily from i...
Zhongzhi Pharmaceutical Sets Board Meeting to Review Interim Results and Possible Dividend
Zhongzhi Pharmaceutical Holdings Limited has scheduled a board meeting in Hong Kong on 26 August 2026 to review and approve the unaudited interim results for the six months ended 30 June 2026. At the same meeting, directors will also consider the dec...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 26, 2026